ReviewWorld journal of hepatology2015
Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure.
Review in World journal of hepatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 53 citations in OpenAlex.
- Trial
- Evaluation of Hepatitis B and C Reactivation in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors.Mediterranean journal of hematology and infectious diseases · 2026Article
- Universal Viral Screening of Patients with Newly Diagnosed Cancer in the United States: A Cost-efficiency Evaluation.Cancer research communications · 2023Article
- The Burden of Hepatitis B, Hepatitis C, and Human Immunodeficiency Viruses in Ovarian Cancer Patients in Nairobi, Kenya.Infectious disease reports · 2022Article
- Reactivation of Occult Hepatitis B Virus Infection During Long-Term Entecavir Antiviral Therapy.Frontiers in microbiology · 2022Article
- Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy.World journal of clinical cases · 2021Review
- Autoimmune Pemphigus: Latest Advances and Emerging Therapies.Frontiers in molecular biosciences · 2021Review
- Infections associated with the new 'nibs and mabs' and cellular therapies.Current opinion in infectious diseases · 2020Review
- The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects.Signal transduction and targeted therapy · 2020Review
- Hepatitis B virus recurrence after liver transplantation: An old tale or a clear and present danger?World journal of gastroenterology · 2020Review
- Hepatitis B Virus Reactivation after Receiving Cancer Chemotherapy under Administration of Leuprorelin Acetate.Internal medicine (Tokyo, Japan) · 2020Article
- Rheumatologists' awareness of hepatitis B reactivation before immunosuppressive therapy.Rheumatology international · 2019Article
- Using glycyrrhizic acid to target sumoylation processes during Epstein-Barr virus latency.PloS one · 2019Article
- Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2018Article
- Outcomes of kidney transplantation in patients with hepatitis B virus infection: A systematic review and meta-analysis.World journal of hepatology · 2018Article
- Liver Illness and Psoriatic Patients.BioMed research international · 2018Review
- Prevention and management of hepatitis B virus reactivation in cancer patients.Hepatology international · 2016Review
- Hepatitis-Associated Liver Cancer: Gaps and Opportunities to Improve Care.Journal of the National Cancer Institute · 2016Article
- Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics.Antiviral research · 2015Review
- Asymptomatic Hepadnaviral Persistence and Its Consequences in the Woodchuck Model of Occult Hepatitis B Virus Infection.Journal of clinical and translational hepatology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to the inherent relationship between the immune system and the hepatitis B virus (HBV) in exposed and infected individuals, immunomodulation associated with the treatment of solid tumours, haematological malignancies and inflammatory disorders has been linked to HBV reactivation (HBVr). Reactivation of HBV infection in the setting of chemotherapy and immunosuppression may lead to fulminant liver failure and death, but there is a cumulative body of evidence that these are potentially preventable adverse outcomes. As chronic hepatitis B is largely asymptomatic but also endemic worldwide, clinicians caring for patients requiring chemotherapy or immunosuppression need to be vigilant of the potential for HBVr in susceptible individuals. Serological screening and prophylactic and pre-emptive antiviral treatment with a nucleos(t)ide analogue should be considered in appropriate settings. Hepatitis B prevalence is examined in this review article, as are the risks of HBVr in patients receiving chemo- and immunosuppressive therapy. Recommendations regarding screening, monitoring and the role of antiviral prophylaxis are outlined with reference to current international associations' guidelines and the best available evidence to date.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.